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The Journal of Immunology
A Novel Computational Model Predicts Key Regulators of
Chemokine Gradient Formation in Lymph Nodes and
Site-Specific Roles for CCL19 and ACKR4
Mohammad Jafarnejad,* David C. Zawieja,† Bindi S. Brook,‡ Robert J. B. Nibbs,x,1 and
James E. Moore, Jr.*,1
The chemokine receptor CCR7 drives leukocyte migration into and within lymph nodes (LNs). It is activated by chemokines CCL19
and CCL21, which are scavenged by the atypical chemokine receptor ACKR4. CCR7-dependent navigation is determined by the
distribution of extracellular CCL19 and CCL21, which form concentration gradients at specific microanatomical locations. The
mechanisms underpinning the establishment and regulation of these gradients are poorly understood. In this article, we have in-
corporated multiple biochemical processes describing the CCL19–CCL21–CCR7–ACKR4 network into our model of LN fluid flow
to establish a computational model to investigate intranodal chemokine gradients. Importantly, the model recapitulates CCL21
gradients observed experimentally in B cell follicles and interfollicular regions, building confidence in its ability to accurately
predict intranodal chemokine distribution. Parameter variation analysis indicates that the directionality of these gradients is
robust, but their magnitude is sensitive to these key parameters: chemokine production, diffusivity, matrix binding site availabil-
ity, and CCR7 abundance. The model indicates that lymph flow shapes intranodal CCL21 gradients, and that CCL19 is func-
tionally important at the boundary between B cell follicles and the T cell area. It also predicts that ACKR4 in LNs prevents
CCL19/CCL21 accumulation in efferent lymph, but does not control intranodal gradients. Instead, it attributes the disrupted
interfollicular CCL21 gradients observed in Ackr4-deficient LNs to ACKR4 loss upstream. Our novel approach has therefore
generated new testable hypotheses and alternative interpretations of experimental data. Moreover, it acts as a framework to
investigate gradients at other locations, including those that cannot be visualized experimentally or involve other chemokines. The
Journal of Immunology, 2017, 199: 000–000.
I
mmunosurveillance and immune responses depend on pre-
cisely coordinated leukocyte migration. This is largely or-
chestrated by chemokines, which are sensed by heptahelical G
protein–coupled chemokine receptors on leukocytes (1, 2). Chemo-
kines induce various types of cell migration, particularly haptotaxis
and chemotaxis, which involve directed cell movement up a con-
centration gradient. The mechanisms that control the formation and
regulation of chemokine gradients in vivo are poorly understood but
likely involve many interrelated biochemical and physical process-
es (3–5). Understanding how these processes are integrated and
modulated remains a major challenge in chemokine biology. In this
article, we develop a computational model of chemokine transport
within the lymph node (LN) to explore the contribution of distinct
physical and biological phenomena to chemokine gradient formation.
Evidence of extracellular chemokine gradients in vivo is mostly
indirect and based on visualizing leukocyte behavior by intravital
microscopy. However, because of its abundance and high affinity for
extracellular matrix (ECM), gradients of CCL21 have been directly
detected in tissues, including in interfollicular regions (IFRs) and
B cell follicles (BFs) of LNs (Fig. 1), where CCL21 concentration
increases toward the T cell area (TC) in the paracortex (6–8). CCR7,
the receptor for CCL21, is critically involved in cell migration in
LNs controlling lymphocyte entry from the blood, intranodal T cell
motility, T cell retention, and the migration of B cells in the BF to
the BF–TC boundary (6, 9, 10). It is also required for dendritic cells
(DCs) to move from the subcapsular sinus (SCS) into the IFR, and
for their subsequent directional migration to the TC (11). CCR7
also binds CCL19, which is produced primarily by stromal cells in
the TC. CCL19 lacks the highly charged extended C terminus
present in CCL21, resulting in a much lower affinity for ECM (12–
15). Consequently, CCL19 and CCL21 will differ markedly in their
distribution and retention in LNs. CCL21 is the dominant CCR7
ligand, and although CCL19 can direct chemotaxis through CCR7
in vitro, it is dispensable for lymphocyte and DC entry into LNs
(16–18). However, it can contribute to T cell homeostasis (18) and
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is thought to control leukocyte behavior inside LNs (19). Inter-
estingly, CCL19 and CCL21 elicit different intracellular signals
through CCR7, and only CCL19 drives CCR7 desensitization
and internalization of ligand–receptor complexes (19–24).
CCL19 and CCL21 also bind to the atypical chemokine receptor
ACKR4 (also known as CCRL1 or CCX-CKR) (25). It is expressed
by lymphatic endothelial cells (LECs) on the SCS ceiling (7) and by
stromal cells in nonlymphoid tissues, such as keratinocytes and
some LECs in skin (17, 26). Although structurally related to CCR7,
ACKR4 cannot drive cell migration but can mediate chemokine
internalization and destruction (7, 26, 27). This scavenging activity
regulates CCR7-directed DC migration in vivo (7, 17, 26). In resting
Ackr4-deficient mice, CCL21 gradients in the IFR of skin-draining
LN (SLN) are swamped by excess CCL21 and DC egress from the
SCS is delayed (7). During cutaneous inflammation, scavenging by
ACKR4 prevents CCL19 from interfering with the CCR7-mediated
detection of CCL21 which is required to direct DC trafficking out of
the skin to the SLNs (17).
CCR7-dependent migration in vivo is ultimately dependent on the
precise distribution of extracellular CCL19 and CCL21. This will be
influenced by many biochemical and physical processes including
the rate or site of production; diffusion in tissue; interaction with
ECM; internalization by CCR7; scavenging by ACKR4; and fluid
flow in blood vessels, lymphatic vessels, and the interstitial space.
To explore this complex process, we have built all these factors
into a novel three-dimensional computational model of chemokine
distribution in skin-draining popliteal LNs (PLNs) by integrating
multiple biochemical processes into our established model of PLN
lymph flow and fluid exchange (28). This has allowed us to predict
how distinct physical and biochemical processes shape chemokine
gradients, and determine which of these processes are likely to be of
particular biological importance. It has also guided the formulation
of novel testable hypotheses to focus future experimentation. More-
over, this comprehensive modeling approach can be used as a
framework to investigate gradients at other locations and involving
other chemokines.
Materials and Methods
We have developed a mathematical model that accounts for the key bio-
logical and physical processes that determine chemokine gradients in LNs,
and solved the resulting complex system of equations computationally. To
do this, we have coupled equations describing chemokine reactions to our
previous model of fluid flow in the LN (28). Application of mathematical
models to biology using this general approach has a long history (29–31),
and such models have been developed in previous studies to describe
general chemokine behavior (4, 5, 29–31). The key interactions regulating
the distribution of extracellular CCL19 and CCL21, and which are mod-
eled in this study, are summarized in Fig. 1A–C.
Modeling LN fluid transport
The model of lymph flow through the PLN is based on our published work
(28). Briefly, we constructed an idealized three-dimensional geometry
based on the general features of a mouse PLN (∼1 mm in diameter), in-
cluding an afferent vessel (Af), an efferent vessel (Ef), and the different
zones of the node (SCS, BFs, TC, medulla) (Fig. 1D). Computer-aided
modeling software (ANSYS, Canonsburg, PA) was used to generate a
computational mesh and solve the equations of fluid flow. Wall shear
stress along the SCS was used as the criterion for mesh refinement (28).
The Navier–Stokes equations were used to describe flow in the fluidic
regions (i.e., Af, SCS, and Ef), and the Darcy law with the Brinkman
term was used in the porous regions (i.e., BF, TC, and medulla). The fluid
exchange between blood vessels and lymphatic compartments was modeled
using the Starling equation. All fluid flow parameters were the same as those
in our previous work (28).
Chemokine transport
The general description of chemokine dynamics consists of two partial
differential equations and six ordinary differential equations (ODEs). The
concentration evolution of transportable species (unbound CCL21 [CCL21u]
and CCL19) are governed by partial differential equations representing
diffusion, advection, and reactions (binding, uptake, and scavenging), as
shown in Supplemental Fig. 1, Eqs. 1 and 2. Concentrations of receptor- and
ECM-bound chemokines, as well as receptor densities, are governed by
ODEs (Supplemental Fig. 1, Eqs. 3–8). These quantities vary among LN
regions but are not transported by diffusion or advection.
CCL21 binding to matrix
The process of CCL21 binding to, and unbinding from, ECM is modeled
with first-order reaction kinetics (Supplemental Fig. 1, Eqs. 1, 3), where the
binding rate constants k1 and k2 were measured by Shields et al. (31) for
CCL21 binding to perlecan as 0.000093 nM21s21 and 0.00012 s21, re-
spectively. The maximum number of CCL21 binding sites associated with
each cell was assumed to be 106, which is similar to Matrigel containing
1% perlecan (Supplemental Fig. 2) (31). The spatially averaged ECM
binding site density in each region of the LN was calculated according to
the process described below in Parameter estimation.
CCR7 binding dynamics
CCR7 can bind to CCL19 or CCL21, but only CCL19 efficiently induces
desensitization and internalization of CCR7 (19–24) (Fig. 1E). For CCL19/
CCR7 binding dynamics, we have employed a simplified version of a pre-
vious model (29) as given in Eqs. 4–6 in Supplemental Fig. 1. We have as-
sumed CCL21u and ECM-bound CCL21 (CCL21b) bind to, but do not
desensitize or internalize, CCR7 (Fig. 1E). They are thus modeled by Eqs. 7
and 8 in Supplemental Fig. 1. The total number of CCR7 molecules per cell
(in all their different states) is assumed to be constant (Supplemental Fig. 1,
Eq. 9). The total number of receptors in each computational element was
calculated based on the continuum assumption explained in Parameter
estimation, and CCR7 expression values are obtained from the Immu-
nological Genome Project (ImmGen) database (Supplemental Fig. 3A)
(32, 33). CCR7 is only located on cell membranes, but we have assumed
that CCR7 in each computational element is uniformly distributed. On
(lon = 0.001 nM
21s21) and off (loff = 0.005 s
21) binding rates to CCR7
are similar for CCL21 and CCL19 and are calculated from dissociation
constants determined experimentally (27, 29, 30, 34, 35). Rate constants
for desensitization (ldes = 0.003 s
21), internalization (lint = 0.0005 s
21), and
recycling (lup = 0.000375 s
21) of CCL19–CCR7 were calculated from
curve fits of experimental data (29, 30) (Supplemental Fig. 2). The max-
imum number of CCR7 molecules per cell is estimated to be 30,000 in the
baseline case.
ACKR4-mediated chemokine scavenging
In LNs, only LECs on the SCS ceiling express ACKR4 (7). A receptor
internalization model was therefore adopted (Fig. 1F) to describe ACKR4
dynamics and CCL19/CCL21u scavenging on the capsule boundary as
given by four additional ODEs (Supplemental Fig. 1, Eqs. 11–14). The
total number of ACKR4 molecules in all its different states per LEC is
assumed to be constant (Supplemental Fig. 1, Eq. 15) and 30,000 in the
baseline case. From the number of LECs we estimated to be in the SCS,
half were assumed to be on the ceiling, which leads to an average cell
diameter of ∼25 mm. The same LEC density was assumed for the capsule
on the medulla. All other molecules are assumed to have zero flux at the
surface of the capsule. Based on our previous studies of ACKR4-mediated
CCL19 scavenging (27), we assumed that receptor resurfacing is the limiting
factor and then set the rest of the reaction parameters of the model to have
similar scavenging rates (hin = 1.0 s
21 and hup = 0.002 s
21). Additionally,
we measured the dissociation constant to be 4.5 nM (27) and set the on and
off rates accordingly (hon = 0.5 nM
21s21 and hoff = 2.25 s
21).
Chemokine transport to blood vessels
Very low concentrations of CCL19 and CCL21 are present in plasma
at physiological conditions (36, 37). In mice, chemokines injected in
the foot pad appear on the luminal surface of PLN blood vessels within
90 min (38). Chemokine transport to blood vessels can occur directly
within LNs by convection from fluid exchange and by diffusion due to
concentration difference. These are indicated by the first and second
terms, respectively, in Eq. 10 in Supplemental Fig. 1. Under basal con-
ditions, some lymph fluid is transported from lymphatic compartments
to blood vessels in the LN, for which the fluid exchange parameters
from the Starling equation are assumed to be the same as in our pre-
vious work (28, 39, 40). CCL19 and CCL21 (8.8–12.2 kDa) molecules
are estimated to have approximately half the radius of albumin (68 kDa)
(41), giving an estimated chemokine permeability of 5 3 1027 cm/s, an
order of magnitude greater than albumin (42).
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Boundary conditions
Eqs. 1–9 in Supplemental Fig. 1 were solved in the steady-state form
(without the transient terms on the left-hand side). To initiate the numerical
solution, starting values of zero were assumed for all variables. Chemokine
concentration was assumed to be constant and equal to zero at the Af inlet
and the Ef outlet, unless otherwise indicated. A quarter of the LN was
modeled with symmetry boundary conditions on the two sidewalls. Steady-
state versions of the ACKR4 Eqs. 11–15 in Supplemental Fig. 1 were
solved at the capsule boundary to determine the scavenging flux for
CCL19 and CCL21u, and were applied as boundary conditions on the
capsule ceiling (Supplemental Fig. 1, Eq. 16). The computational code was
then run until the solution converged to a steady state.
Parameter estimation
Because of the complexity of having different cell types in multiple regions
in the LN, we have used gene expression data from ImmGen (Supplemental
Fig. 3A) to identify the dominant expression pattern. This leads to a set of
simplifying assumptions that greatly reduce the number of free parameters
in the model. We have assumed that the cell types are homogenously
distributed within each of the regions (Supplemental Fig. 3B) and that the
protein levels are proportional to the expression values obtained from
ImmGen (Supplemental Fig. 3A) (32, 33). With this we can calculate the
parameters of interest by multiplying the total cell number types by the
percentage of cells in the particular region and the expression level, nor-
malized by the computational element volume size (Supplemental Fig. 1,
Eq. 17) (43–45). For example, for the total number of CCR7 molecules in
the TC, we multiply the total number of T cells, Nk (∼106 in PLN;
Supplemental Fig. 3B), by the percentage of T cells (cell type k) in the TC
(region j), Pk,j (0.9, Supplemental Fig. 3B); then multiply this by the
normalized CCR7 expression value for T cells, EVX,k (0.5, Supplemental
Fig. 3A), and maximum possible CCR7 per cell, Xmax (30,000). We then
divide by the Avogadro number, NA, to find the total moles of CCR7 on
T cells in the TC. Assuming homogenous distribution, we scale the total
moles with the volume of the computational element (Voli) with respect to
the volume of the TC (Volj) to find the moles of CCR7 in that element.
Summing all the moles of CCR7 from different cell types, k, (B cell, T cell,
DC, macrophage, LEC, blood endothelial cell, and fibroblastic reticular
cell) provides an estimate of total moles of CCR7 in that computational
element. Similarly, we estimated the rate of CCL19 production (Fig. 1G),
the rate of CCL21 production (Fig. 1H), CCR7 density (Fig. 1I), and ECM
binding site density (Fig. 1J).
Parameter variation analysis
Latin hypercube sampling was used to test the robustness of the model and
to investigate the effect of variation in seven biological parameters on
gradients of CCL21 and CCL19. These were selected because of their
potential biological importance, previous investigations in animal models,
and the level of confidence in their estimation from previously published
data. The input parameters and bounds on their distribution are shown in
Supplemental Fig. 3C. From simulations with 100 different input param-
eter combinations, we quantified the slopes of the CCL19/CCL21b con-
centration profiles (along the arrows shown in Fig. 1D), the total amounts
of CCL19 and CCL21 in the whole LN, and Ef concentrations of CCL19
and CCL21. The volume integral of the concentration over LN volume was
used to calculate total CCL19 and CCL21 (CCL21u and CCL21b). Partial
rank correlation coefficients (PRCCs) were calculated to identify positive
and negative correlations between the main input parameters and the
outputs (46, 47). The Student t test was used to determine the significance
of the PRCCs. MATLAB R2013a (MathWorks) was used for PRCC cal-
culation and statistical analysis.
Calculation of concentration difference across cells
Spatial concentration differences were calculated based on concentra-
tions Ci (i = 1..N) at N locations along the direction of interest. The dif-
ference across a cell is Ci+1 2 Ci for i = 1..N21. As previously (8), each
location was separated by 9, 18, or 36 mm to cover a range of cell sizes
from small lymphocytes to larger DCs (Fig. 1K). Along the arrows
(Fig. 1D), the baseline gradients were resampled at a spatial resolution of
4.5 mm and low-pass filtered.
Results
Baseline computational simulations generate intranodal
chemokine gradients
In baseline computational simulations of intranodal steady-state
chemokine distribution, the highest concentrations of CCL19,
CCL21b, and CCL21u occurred in the center of the TC (Fig. 2A–C).
CCL21b, at a maximum concentration of 306 nM, was much more
abundant than CCL19 or CCL21u (maximum concentrations of 0.9
and 5.2 nM, respectively). Consistent with experimental observations
(7), gradients of CCL21 (CCL21u and CCL21b) were observed in
the IFR. The model also predicts that a CCL19 gradient forms here.
The CCL19 and CCL21u gradients had a nearly uniform magnitude
(∼0.003 and ∼0.018 nM/mm, respectively), whereas the CCL21b
gradient was highest at the border with the SCS (3.7 nM/mm) and
dropped by nearly an order of magnitude, 200 mm from the SCS
floor (Fig. 2F). Nonetheless, the IFR gradient of CCL21b was at least
17 times larger than those of CCL19 or CCL21u.
Chemokine gradients were also present across the BF–TC
boundary and into the BF (Fig. 2H–K). CCL21b and CCL19 were
virtually absent from BFs so large gradients formed at the BF–TC
boundary. The CCL19 gradient was at most 0.004 nM/mm, whereas
that of CCL21b was 10 nM/mm over a 25 mm region. The simu-
lations also predicted the existence of gradients of CCL21u (0.008–
0.023 nM/mm) that emanated from the TC but extended deeper into
the BF than the CCL19 and CCL21b gradients, virtually reaching
the SCS. These were similar in shape to those present in the IFRs. A
CCL21 gradient leading to the BF–TC border has been detected
immunohistochemically in BFs (6).
Thus, baseline simulations predict gradients of CCL19, CCL21u,
and CCL21b at two locations in LNs. The gradients of CCL21
resemble those that have been experimentally observed, building
confidence in the ability of the computational model to accurately
predict intranodal chemokine distribution.
Concentration differences across representative cell sizes
Next, we considered how these gradients might be interpreted by
leukocytes. Directed migration depends on a cell sensing a che-
mokine concentration difference between its leading and trailing
edges. This is determined computationally by the magnitude of
the gradient and the cell size (Fig. 1K), and was calculated across
cells with 9, 18, or 36 mm diameters with their leading edge
pointing toward the TC (Fig. 3). We considered cells in IFRs
(from the SCS ceiling to the TC) (Fig. 3A, 3B), and those in BFs,
across the BF–TC border and into the TC (Fig. 3C, 3D). The data
are presented both as a total concentration difference (Fig. 3A, 3C)
and as a percentage concentration difference (Fig. 3B, 3D). As
expected, concentration differences were always positive for all
chemokines, and there was a linear relationship between cell size
and concentration difference, with larger differences seen by
larger cells. The absolute concentration differences of CCL19 and
CCL21u did not vary much within different regions of the IFR for
a cell of a given size (Fig. 3A). Those for CCL21b were of a much
higher magnitude (up to ∼110 nM at the SCS floor), but they got
substantially smaller with increasing distance from the SCS
(Fig. 3A). The profiles of the percentage concentration differences
were broadly similar for CCL19, CCL21u, and CCL21b, with by
far the greatest difference seen for all at the SCS floor due to their
very low concentrations in the SCS (Fig. 3B).
Large CCL21b concentration differences were present around
the BF–TC border (Fig. 3C, 3D). However, concentration differ-
ences in CCL19, and particularly CCL21u, were present through-
out the BF in addition to the BF–TC border (Fig. 3C, 3D). The
largest percentage of CCL21u concentration differences were
just underneath the floor of the SCS, whereas regions of the BF
closer to the BF–TC border showed the largest percentage of
CCL19 concentration differences (Fig. 3D). We also considered
cells in the TC and at the BF–TC border with their leading edge
pointing toward the SCS: as expected, concentration differences
were negative for all chemokines and became increasingly negative
The Journal of Immunology 3
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FIGURE 1. Methodological information on building the model. (A–C) Schematic of LN with CCL19 and CCL21 interactions. (A) Schematic showing
lymph entry into SCS from the Af, after which it can percolate into BFs and T cell paracortex (TC) and be exchanged with blood vessels; or flow via the
medulla (ME) into the Ef. (B and C) Interactions of CCL19 (B) or CCL21 (C): each arrow indicates a reaction or transport term in the model. (D) Idealized
LN geometry used in the computational model with regions color coded. Abbreviations as in (A). Red arrows indicate the locations where concentration
gradients were measured. (E and F) Reaction diagrams for chemokine interactions with CCR7 and ACKR4. (E) CCR7 is desensitized and internalized after
binding CCL19, after which CCR7 returns to the cell surface and CCL19 is degraded. CCL21–CCR7 interactions use ligand–receptor models without
desensitization or internalization. (F) Binding of CCL19 or CCL21u to ACKR4 results in chemokine internalization and degradation, and subsequent
recycling of ACKR4 to the cell surface. (G–J) Distribution of CCL19/CCL21 production, CCR7 density, and matrix binding site density in the PLN.
Assuming homogenous cell distribution within each PLN region, CCL19 production (G), CCL21 production (H), CCR7 concentration (I), and matrix
binding site concentration (J) were calculated for each region using Eq. 16 in Supplemental Fig. 1. Production rates or concentrations are color coded
according to scales to the right of each image. (K) Sample concentration profiles illustrating how gradients and concentration (Figure legend continues)
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as cells in the TC were positioned closer to the BF–TC border (data
not shown).
Thus, IFR gradients appear capable of directing cells out of the
SCS and then deeper into the TC. Cells in the BF have the potential
to be drawn toward and across the BF–TC border in response to
CCR7 ligands, but the precise location of the cell will likely de-
termine whether it responds to CCL19, CCL21u, and/or CCL21b.
Conversely, cells in the TC will encounter increasingly negative
concentration differences as they approach the BF–TC border.
Regional variations in chemokine–CCR7 complexes
The analysis above gives a clearer picture of how CCR7+ cells might
sense gradients predicted by the model, but very high or very low
levels of receptor occupancy, along with receptor desensitization and
internalization, have implications for the ability of gradients to in-
duce migration. Therefore, we next examined CCR7 occupancy and
CCL19-driven CCR7 desensitization/internalization in the LN un-
der baseline conditions (Fig. 4). Based on the distribution of CCR7+
leukocytes in LNs, CCR7 was modeled as being absent from the
SCS, low in the medulla, and abundant in the TC and BF (Fig. 1I).
Virtually all CCR7 molecules in the TC and IFR were predicted
to be occupied by chemokine, the vast majority by CCL21b (Fig.
4B), with only ∼2% available for CCL21u or CCL19 (Fig. 4C, 4E);
although there was a small amount of unbound CCR7 present at the
border between the SCS floor and the IFR (Fig. 4A). Exposure to
CCL19 in the core of the TC was predicted to result in the inter-
nalization and desensitization of virtually none (,1%) of the
available CCR7 molecules (Fig. 4F, 4G).
In the BF, the absence of CCL21b meant that more CCR7 here
was unoccupied and therefore available for binding to CCL21u or
CCL19 originating from the TC (Fig. 4C–E). The number of re-
ceptors occupied by CCL21u and CCL19 increased with prox-
imity to the BF–TC border, before plummeting abruptly once the
border was crossed. The peak concentrations of CCL21u–CCR7
(Fig. 4C, 4D) and CCL19–CCR7 (Fig. 4E, 4H) complexes near
the BF–TC border were 44.2 and 1.4 nM, respectively. Con-
versely, unbound CCR7 was at its highest at the edge of the BF
adjacent to the SCS (Fig. 4A, 4D), although some CCL21u–CCR7
complexes were still present even in this region of the BF (Fig. 4C,
4D). Interestingly, there was a striking peak of CCL19-driven
CCR7 desensitization and internalization in the BF adjacent to
the BF–TC border; this was absent from regions deeper in the
BF, and four- to fivefold higher than in the TC (Fig. 4F–H).
Thus, the model predicts that the intranodal distribution of
CCR7 ligands leads to wide variation in CCR7 occupancy and
desensitization/internalization between, and within, distinct mi-
croanatomical niches. This has implications for how these che-
mokine gradients might direct and control cell migration at
specific locations (see Discussion).
Parameter variation analysis
Parameter variation analysis (PVA) provides a means of evaluating
variations and uncertainties in input parameters that may be key
regulators of a model’s outputs and, by extension, the physio-
logical process being modeled. With this approach, we determined
which parameters are key in determining the intranodal gradients
of CCL19, CCL21u, and CCL21b generated by our model. One
hundred simulations were run in which random variations were
simultaneously introduced into each of the following parameters:
intranodal production of CCL19 or CCL21, the number of CCR7
or ACKR4 receptors (on cells known to express these receptors),
the concentration of ECM binding sites, and the effective diffusion
coefficient of each chemokine (Deff). The upper and lower limits
used in these simulations are detailed in Supplemental Fig. 3C.
We examined the shape and directionality of chemokine gradi-
ents formed in these simulations (Fig. 5A–C, E–G) and explored
whether correlations existed between any of the randomly gen-
erated variations and either 1) the amount of chemokine in the LN
or efferent lymph (CCL19 or CCL21u and CCL21b), or 2) the
magnitude of the gradient across the BF–TC border (Fig. 5H) or in
the IFR immediately underneath the SCS (Fig. 5D).
As expected, CCL21b was muchmore abundant than CCL19 and
CCL21u in all simulations (Fig. 5). When there were elevated
quantities of CCL21b in the IFR, a step gradient formed at the
floor of the SCS (Fig. 5C). Importantly, the concentration profiles
clearly showed that although gradient magnitude varied consid-
erably across the simulations, the intranodal gradients of CCL19,
CCL21u, and CCL21b maintained their directionality, increasing
in concentration from the floor of the SCS into the TC, and from
the BF across the BF–TC border (Fig. 5). However, various cor-
relations were found between the randomly modified parameters
and either the amount of chemokine (in the LN or efferent lymph)
or the magnitude of the gradients immediately underneath the SCS
or across the BF–TC border (Table I).
First, there was a strong correlation between the ECM binding
site concentration and the magnitudes of the CCL21b gradients
under the SCS and across the BF–TC border. In addition, lower
matrix binding site concentrations correlated with decreasing
amounts of CCL21 and CCL19 in the LN. This was positive for
CCL21, because decreased ECM reduced CCL21b accumulation,
but negative for CCL19 because a drop in CCL21b increased free
CCR7 to enhance CCR7-mediated CCL19 internalization and
degradation. For the same reason, the level of CCL21 production
positively correlated with both total CCL21 and total CCL19 in
the LN, whereas production of CCL19 only correlated with levels
of CCL19. Similarly, increased ECM binding sites, CCL21 pro-
duction, or CCL19 production correlated with the accumulation
of CCL19 in efferent lymph. Again, because of CCR7-mediated
CCL19 internalization, there were strong negative correlations
between the quantity of CCR7 in the LN and CCL19-related pa-
rameters (i.e., gradient magnitude, total amount in LN and efferent
lymph). Correlations between the CCR7 level and CCL21-related
parameters were less apparent, although weak positive correla-
tions existed between CCR7 and the IFR CCL21 gradient mag-
nitude, and the amount of CCL21 in efferent lymph. There were
strong negative correlations between the effective diffusivity of
differences across cells were calculated. Chemokine concentration profiles (blue curves) are plotted as a function of distance along a predefined direction [e.g.,
red arrows in (D)]. The gradient is the slope of the profile at a particular location (red and magenta lines). If the concentration profile is nonlinear, then the
magnitude and/or sign of the gradient vary with position. A cell’s size determines the concentration differences it can sense, e.g., cell 1 at position x1 senses a
larger concentration gradient (DCCell 1) than a smaller cell, cell 2, at the same location (DCCell 2). In different profiles there may be the same concentration
difference across a cell (e.g., the magenta gradients in profiles 1 and 2 are of the same magnitude, so DCCell 3 would have the same value in both cases).
However, if these are normalized with respect to the absolute concentration values at one edge of the cell (e.g., C1 and C2), then the percentage con-
centration difference will be greater for the cell in profile 1 than in profile 2. We therefore also plot the percentage concentration difference across a cell.
Directionality (i.e., the direction in which a cell migrates) depends on the sign of the gradient. Given that leukocytes typically migrate up concentration
gradients, cells will be predicted to migrate in the positive direction (e.g., from x1 to x2) where gradients are positive (red lines), and in the opposite
direction (e.g., from x3 to x2) where they are negative (magenta lines).
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CCL19 and CCL21 and the magnitude of their respective gradi-
ents under the SCS and across the BF–TC border. At the same
time, higher effective diffusivity reduced the total amount of
chemokines in the LN, while increasing their presence in efferent
lymph. Finally, the number of ACKR4 molecules per LEC on the
ceiling of the SCS did not significantly correlate with changes in
gradients of CCL19 and CCL21, or the total amount of chemokine
in the LN, but did negatively correlate with the concentration of
CCL19 and CCL21 in efferent lymph.
These data demonstrate that gradient directionality is a stable
output from the model. However, variations in key biological or
physical parameters affect the magnitudes of these gradients and/or
the total amount of chemokine in the LN or efferent lymph.
Role of ACKR4 in LN versus peripheral tissue
IFR CCL21 gradients are disrupted in the SLNs of Ackr4-deficient
mice due to the accumulation of excess extracellular CCL21 (7),
yet our PVA indicated that variation in ACKR4 activity on the
SCS ceiling has no impact on gradient formation in LNs. Indeed,
intranodal distributions of CCL19, CCL21u, and CCL21b were
unaffected by the complete removal of ACKR4 from baseline
simulations (Fig. 6A, 6B, 6E, 6F). However, this scenario, referred
to in this study as “LN ACKR4 knockout (KO),” does not consider
the impact that loss of ACKR4-mediated chemokine scavenging
from the skin, a rich source of ACKR4 (17, 26), has on intranodal
chemokine distribution; the excess CCL21 seen in the IFR of
Ackr4-deficient SLN might originate in the skin and enter the SLN
via afferent lymph. To explore this, we considered two scenarios:
1) “skin ACKR4 KO,” which resembled the baseline simulation
(referred to in Fig. 6 as wild-type [WT]) except that CCL21 and
CCL19 were added to afferent lymph to mimic loss of ACKR4
from the skin (i.e., Cin,CCL19 = Cin,CCL21 = 5 nM) (Fig. 6C); and 2)
“global ACKR4 KO,” where simulations were similar to 1) but in
which ACKR4 was also absent from the SCS ceiling (Fig. 6D),
mimicking global loss of ACKR4. These two simulations pro-
duced identical CCL19, CCL21u, and CCL21b contour maps in
which most of the intranodal chemokine gradients seen in WT and
LN ACKR4 KO were substantially altered (Fig. 6). CCL21b
concentrations were higher in the IFR and the CCL21b gradient
was virtually eliminated, akin to the IFR distribution of CCL21
seen experimentally in Ackr4-deficient SLN (7). In addition, the
CCL19 IFR gradient directly under the SCS was reversed. The
FIGURE 2. CCL19 and CCL21 form gradients in the IFR and BF–TC border of the LN. Contours of concentrations of CCL19 (A), CCL21u (B), and
CCL21b (C) in an LN with an idealized geometry. The depth of color in (A)–(C) gives an indication of concentration, according to the scales shown in each
panel. The IFR (D–F) and BF–TC border (H–J) concentration profiles are quantified along the red arrows indicated (G and K) for each of the corresponding
contours. All profiles start from the ceiling of the SCS and include the sinus (10 mm height). Vertical solid lines in (H)–(J) show the location of BF–TC
border at 188 mm from the SCS.
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CCL21b and CCL19 gradients at the BF–TC border were less
markedly affected, but a new CCL19 gradient was present in the
BF under the SCS. At both of these locations the directionality
and magnitude of the CCL21u gradient was unchanged, although
there was an increase in CCL21u concentration throughout the
LN. Further simulations incorporating lower concentrations of
chemokine in afferent lymph resulted in similarly shaped chemo-
kine profiles, with magnitudes varying monotonically between
those seen for the global ACKR4 KO and WT (data not shown).
Disrupting lymph flow alters intranodal chemokine distribution
and unmasks a role for ACKR4 on the SCS ceiling
Next we explored the role of lymph flow in shaping intranodal
gradients by performing simulations in which the flow rate was
decreased to 1% of the baseline (Fig. 7A, 7B, 7E, 7F). This
resulted in an increase in the concentration of all the chemokines
throughout the TC, and although there were minimal changes in
the magnitude and directionality of the CCL19 and CCL21u
gradients, the CCL21b gradient in the IFR was noticeably re-
duced. There was also a marked accumulation of CCL21u, and
particularly CCL21b, in the SCS; the concentration of all three
chemokines was increased in the medulla; and CCL19 and
CCL21u were present in efferent lymph. Thus, the model predicts
that lymph flow shapes intranodal chemokine gradients and con-
tributes to the clearance of chemokines from the SCS, medulla,
and efferent lymph.
We wondered whether ACKR4 might limit the accumulation of
chemokines in the SCS seen at low flow rates. Thus, we performed
a further simulation in which we removed ACKR4-mediated scav-
enging from the SCS while simultaneously decreasing the flow rate
to 1% of the baseline (Fig. 7D–F). Interestingly, this exaggerated the
changes in chemokine distribution seen with low flow rate alone
(Fig. 7B, 7E, 7F), contrasting the lack of effect seen when ACKR4
was removed in the context of baseline flow rates (Fig. 7C, 7E, 7F).
Most notable were the increased accumulation of chemokines in
the medulla and efferent lymph; the further reduction in magnitude
of the CCL21b gradient in the IFR; and the marked increase in
CCL21u concentration in the TC, BF, and SCS. These data indicate
that ACKR4-mediated scavenging at the SCS ceiling is dispensable
at times of efficient lymph flow, but helps stabilize intranodal che-
mokine distribution when lymph flow is compromised.
FIGURE 3. Chemokine concentra-
tion difference across cells in the IFR
and at the BF–TC border. Concen-
tration differences across a cell were
calculated for CCL19 (blue), CCL21u
(red), and CCL21b (black) using the
baseline chemokine distribution data
(Fig. 2) for cells with a diameter of 9,
18, and 36 mm with their leading edge
pointing away from the SCS. (A and
B) IFRs. (C and D) BF, BF–TC bor-
der, and TC. The data are presented
as a total concentration difference (A
and C) and as a percentage concentra-
tion difference (B and D). Thirty six–
micrometer cell (solid lines), 18-mm
cell (dashed lines), and 9-mm cell
(dotted lines). Vertical solid lines in (C)
and (D) show the location of BF–TC
border at 188 mm from the SCS.
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Discussion
The mechanisms that control extracellular chemokine distribution
are of significant immunological importance but they are currently
poorly understood. Computational modeling offers a valuable
enhancement to experimental approaches, and can be exploited to
predict the probable outcomes of technically challenging or pro-
hibitively expensive scenarios. Moreover, whereas reductionist
experimental approaches are well suited for investigating indi-
vidual mechanisms, modeling can integrate all relevant mecha-
nisms to build a deeper understanding of how the whole system
functions. To our knowledge, we have developed the first math-
ematical model of LN chemokine transport to include the im-
portant effects of lymph flow and fluid exchange with blood
vessels, as well as incorporating binding dynamics between che-
mokines, receptors, and ECM. The proper construction and initial
validation of such a model is firmly grounded in experimental
evidence, but importantly the model we have developed has
allowed us to predict the key processes regulating chemokine
distribution and gradient formation in LNs as well as generate
new testable hypotheses and provide alternative interpretations
of existing experimental data.
Two key factors build confidence in the reliability of our model
to predict the location of intranodal chemokine gradients. First,
despite substantial changes to the input data in the PVA, the
gradients predicted in the baseline simulation were robust in that
they were always present in the IFR, BF, and BF–TC border, and
their directionality was unchanged. Thus, any inaccuracies in the
input parameters used in the baseline simulation might result in
imprecise predictions of gradient magnitude, but they will not
impact on the model’s ability to predict their location or direc-
tionality. Second, CCL21 gradients similar to those predicted have
been detected in the IFR and BF by immunostaining WT LN
sections with anti-CCL21 Abs (6, 7). This approach presumably
detects ECM-bound chemokine (CCL21b), because most, if not
all, unbound chemokine will be lost during tissue preparation and
processing. Moreover, it remains technically very challenging to
detect extracellular chemokine gradients in situ, and to our
knowledge this has only been achieved for CCL21 in mice, pre-
sumably because of its very strong affinity for the ECM. This
emphasizes the need for alternative approaches, including com-
putational modeling.
The CCR7-dependent egress of DCs from the SCS (11) likely
requires CCL21 bound to LECs on the SCS floor; any unbound
chemokine in the SCS will be washed away by the dominant fluid
flow toward the medulla. Immediately after DC egress, CCL21b in
the IFR would be expected to activate integrin-mediated adhesion
of DCs to fibroblastic reticular cells, and perhaps give some early
directionality to the cells. However, our data show that the very
high CCL21b concentrations in the IFR and TC mean that virtu-
ally all CCR7 receptors are occupied by CCL21b. This high oc-
cupancy, which in an LN would only occur on parts of the DC in
direct contact with CCL21b-coated surfaces, would be expected
to prevent DCs from sensing CCL21b concentration differences
across its length. However, elegant in vitro experiments have
shown that gradients of unbound CCR7 ligands can steer DCs
adhered to surfaces by CCL21b-mediated integrin activation (15).
DCs can therefore interpret information transmitted by unbound
ligands through CCR7 even when CCL21b occupies all the CCR7
molecules on the adhered surface. Thus, in the IFR, CCL21b-rich
surfaces might be responsible for DC adherence, but the gradients
of CCL19 and/or CCL21u observed in the model, rather than
those of CCL21b, could be responsible for steering DCs toward
the TC.
The absence of CCL21b from the BF means that, in contrast to
cells in the TC and IFR, most CCR7 molecules on cells in this area
are unoccupied. Naive B cell homing to BFs requires CXCR5,
which is activated by CXCL13 on follicular stromal cells (48).
However, B cell migration within BFs depends on integrated re-
FIGURE 4. Regional variations in the occupancy, internalization, and desensitization of CCR7. Contours of concentrations (in nM) of unbound CCR7
(A); CCR7 bound to CCL21b (B), CCL21u (C), or CCL19 (E); or CCR7 desensitized (F) or internalized (G) as a consequence of binding to CCL19. The
concentrations of each form of CCR7 at specific parts of the LN are shown in different colors according to the scales shown to the right of panels (A)–(C) or
(E)–(G). During the simulations, it was assumed that CCR7 is absent from Af, SCS, and Ef, and that the total concentration of CCR7 is constant in each
region. (D and H) Concentration profiles from the SCS through the BF and across the BF–TC border (i.e., along the dashed red arrow shown in Fig. 1D).
The graphs in (D) and (H) have been generated from the contour plots in (A)–(C) and (E)–(G), respectively, and the identity of the lines in these graphs is
indicated above the contour plots.
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sponses through CXCR5, CCR7, and EBI2, a receptor for oxy-
sterols (thought to form gradients in the BF toward the SCS) (49,
50), and it will be of interest to incorporate CXCL13, oxysterols,
and their receptors into the computational model. Experimental
approaches have revealed that CCR7 draws naive and Ag-
activated B cells toward the BF–TC border, EBI2 attracts them
toward the SCS, and CXCR5 aids their retention in the BF. Dy-
namic changes in the balance of activity of EBI2 and CCR7 en-
able naive B cells to patrol the BF and directs Ag-activated B cells
first toward the SCS (to enhance Ag capture) and then to the BF–
TC boundary (to search for cognate follicular helper T cells).
Thus, Ccr7-deficient naive B cells accumulate near the SCS-
proximal region of the BF, whereas artificially increasing CCR7
expression causes B cells to enter the TC, and CXCR5 over-
expression prevents CCR7-driven, Ag-induced B cell movement
to the BF–TC border (10).
The integration of our modeling outputs with these experimental
findings leads to new hypotheses concerning the role of CCR7
ligands in the BF. The first is that a gradient of CCL21u is a major
factor controlling CCR7-mediated B cell movement in the BF
because it reaches deep into the BF from the TC. Testing this
hypothesis is challenging given the profound impact of Ccl21
deficiency on LN structure and function (51), and our inability to
distinguish the functions of CCL21u from those of bound CCL21
in vivo. The second hypothesis is that CCL19-induced desensiti-
zation and internalization of CCR7 regulates cell behavior at the
BF–TC border. This is more amenable to experimental testing
because Ccl19 deficiency has no detectable impact on LN struc-
ture (18, 23). For naive B cells, which have relatively low levels of
CCR7, we hypothesize that a CCL19-induced reduction in CCR7
activity at the BF–TC border will allow signals through CXCR5
and EBI2 to dominate and that this will direct cells away from the
BF–TC border to scan for Ag elsewhere in the BF. For Ag-
activated B cells, which have higher levels of CCR7, a brake on
CCR7 activity near the BF–TC border could hypothetically pre-
vent CXCR5-mediated BF retention signals from being over-
ridden by CCL21b-mediated signals through CCR7, thereby
helping retain these cells at the BF–TC border. These hypotheses
are testable using two-photon microscopy and immunohistology
to track the movement and localization, respectively, of adoptively
transferred Ag-specific B cells in the PLNs of WT and Ccl19-
deficient recipients before and after immunization. Ab responses
should be carefully examined in Ccl19-deficient mice, particularly
after immunization with low doses of Ag when the precise lo-
calization of naive and activated B cells might be expected to be of
most importance.
Other significant outputs from the model relate to the role of
lymph flow and ACKR4. During normal lymph flow, ACKR4-
mediated scavenging by LECs on the SCS ceiling had no effect
on gradients, and PVA found no correlation between LN ACKR4
levels and the magnitude of the intranodal gradient. However,
simulating loss of ACKR4-mediated scavenging from upstream
tissue generated a distribution of CCL21 resembling that seen in
Ackr4-deficient mice (7). The gradients of unbound chemokines in
FIGURE 5. PVA. One hundred simulations were run containing randomly generated variations in key parameters controlling intranodal gradient for-
mation. (A–C) Concentration profiles of CCL19 (A), CCL21u (B), and CCL21b (C) in the IFR. (E–G) Concentration profiles of CCL19 (E), CCL21u (F), and
CCL21b (G) at the BF–TC border. The three bold lines in (A)–(C) and (E)–(G) are unrelated representative concentration profiles that have been highlighted
to illustrate the types of gradients observed. (D and H) Individual representative CCL21b concentration profiles from the IFR (D) and BF–TC border (H)
overlaid with red lines that show where the gradient magnitude was measured for the correlation analysis (Table I).
Table I. Results of PVA are summarized for key model outputs (for CCL19 and CCL21) and significantly correlated input parameters
Input Parameter
Output Parameter
Interfollicular
CCL19
Gradient
Interfollicular
CCL21b
Gradient
BF–TC
Border
CCL19
Gradient
BF–TC
Border
CCL21b
Gradient
Total
CCL19
in LN
Total
CCL21
in LN
Efferent
CCL19
Concentration
Efferent
CCL21
Concentration
Matrix binding sites + + + + + + + + + + + + + + + + + +
CCL19 production + + + + + + + + + + + +
CCL21 production + + + + + + + + + + + + + + + + +
CCR7 per cell 2 2 + 222 2 2 2 +
ACKR4 per cell 2 2 2 2 2 2
Effective diffusivity 2 2 2 2 2 2 2 2 2 2 2 222 222 + + + + + +
Significant PRCC values are as follows: +/2, 0.001 , p , 0.01; + +/2 2, 0.0001 , p , 0.001; + + +/2 2 2, p , 0.0001.
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FIGURE 6. Simulations of the im-
pact of Ackr4 deficiency in SCS and/or
skin on intranodal chemokine distri-
bution. Contours (A–D) and plotted
gradients (E and F) in SLN of CCL19
(left column, blue), CCL21u (middle
column, red), and CCL21b (right col-
umn, black) in the following simula-
tions: (A) WT control [solid lines in
(E) and (F)], (B) Ackr4 deficiency in
the LN only (LN ACKR4 KO) [solid
lines in (E) and F)], (C) Ackr4 defi-
ciency in the skin only (skin ACKR4
KO) [dashed lines in (E) and F)], and
(D) combined Ackr4 deficiency in skin
and SLN (global ACKR4 KO) [dashed
lines in (E) and F)]. The inclusion of
5 nM CCL19 and CCL21 in afferent
lymph was used to simulate the levels
of cytokines associated with Ackr4
deficiency in the skin. Plots in rows (E)
(IFR) and (F) (BF–TC border) are
concentration profiles along the arrows
indicated in Fig. 1D. Note in (E) and
(F) the WT control and LN ACKR4
KO lines are indistinguishable (solid
lines), whereas skin ACKR4 KO and
global ACKR4 KO are overlapping
(dashed lines).
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the IFR and BF were also substantially altered in these simula-
tions. CCL19 and CCL21 are present in skin-draining afferent
lymph of humans at concentrations of 0.016 and 0.011 nM, re-
spectively (37), but these chemokines have not been measured in
afferent lymph in WT or Ackr4-deficient mice. However, ACKR4
has been shown to limit the transport of endogenous CCL21 from
peripheral tissues to SLNs in vivo by experiments demonstrating
that SLNs from Ackr4-deficient plt/plt mice contain more CCL21
FIGURE 7. Disrupting lymph flow
alters intranodal chemokine distribu-
tions and unmasks a role for ACKR4
on the SCS. Contours (A–D) and
plotted gradients (E and F) of CCL19
(left column, blue), CCL21u (middle
column, red), and CCL21b (right
column, black) in the following sim-
ulations: (A) baseline flow in the
presence of ACKR4 [solid lines in (E)
and (F)], (B) 1% baseline flow in the
presence of ACKR4 [dashed lines in
(E) and (F)], (C) baseline flow in the
absence of ACKR4 [solid lines in (E)
and (F)], and (D) 1% baseline flow in
the absence of ACKR4 [dash–dot
lines in (E) and (F)]. Plots (E) and (F)
are concentration profiles along the
arrow indicated in Fig. 1D. Note the
+Flow+ACKR4 and +Flow2ACKR4
lines are indistinguishable at these
plot scales.
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than SLNs from plt/plt mice (7). The plt mutation deletes Ccl19
and the Ccl21 gene responsible for producing CCL21 in LNs, but
the Ccl21 gene that generates CCL21 in nonlymphoid tissues
remains intact (51–53). Thus, the excess CCL21 in the SLN of
Ackr4-deficient plt/plt mice must be of nonlymphoid origin.
Lymph flow rate emerged as a key regulator of chemokine
distribution in the model. Thus, in the baseline simulation, any
unbound chemokine leaving the LN parenchyma is washed away in
lymph rather than being scavenged by ACKR4. However, low
lymph flow simulations unmasked a potential role for ACKR4 on
the SCS ceiling: under these conditions ACKR4 clearly stabilized
intranodal gradients and limited chemokine accumulation in the
LN and efferent lymph. Physiologically, ACKR4 on the SCS
ceiling might be important in stabilizing chemokine distribution
during the early inflammatory phases of immune responses when
lymph flow from the affected upstream tissues is diminished and
these tissues swell.
These observations present several additional new hypotheses.
The first is that, under conditions of normal lymph flow, ACKR4 in
the skin, rather than on the ceiling of the SCS, regulates chemokine
gradients and DC trafficking in SLNs. This could be tested using
mice in which Ackr4 alleles can be conditionally deleted. Al-
though currently unavailable, they would allow Ackr4 to be spe-
cifically removed from keratinocytes, the dominant source of
ACKR4 in the skin; or from LECs, the only cell type expressing
ACKR4 in LNs. Alternatively, LN transplantation experiments
could be undertaken between WT and Ackr4-deficient mice. In-
terestingly, in contrast to the SLN (7, 17), CCR7-dependent DC
trafficking to the gut-draining mesenteric LN is unaffected by
Ackr4 deficiency, either at steady state or in response to inflammation-
induced mobilization (R.J.B. Nibbs, unpublished observations).
This is despite skin-draining and mesenteric LNs both making
large quantities of CCL21 and both expressing ACKR4 on LECs
lining the SCS ceiling (R.J.B. Nibbs, unpublished observations).
These observations are consistent with the idea that it is the
characteristics of the tissue upstream that are critical in deter-
mining the impact of Ackr4 deficiency on chemokine gradients
and leukocyte trafficking in draining LNs.
The second hypothesis is that intranodal gradients of CCL21u
and CCL19 can, like those of bound CCL21, be disrupted in
Ackr4-deficient SLNs by excess chemokine entering into the
lymph. It is not possible to visualize these gradients or distin-
guish the functions of CCL21u from those of bound CCL21 in
vivo, but, by generating Ackr4/Ccl19 doubly deficient mice, it is
possible to determine if CCL19 contributes to aberrant migration
into or within LNs caused by Ackr4 deletion. Indeed, Ccl19 de-
letion rescues the defective departure of DCs from the inflamed
skin of Ackr4-deficient mice (17).
The third hypothesis is that reducing lymph flow rate will alter
CCL19/CCL21 distribution and the migratory behavior of CCR7+
leukocytes in LNs, and that this will be particularly evident in
Ackr4-deficient mice. To test this, lymph flow into LNs of WT and
Ackr4-deficient mice would need to be stopped or reduced; this is
technically challenging but could theoretically be achieved by the
ligation or partial ligation of some or all of the afferent lymphatic
vessels entering a specific LN. IFR gradients of bound CCL21
could then be visualized and quantified (7); the levels of CCL19
and CCL21 in efferent lymph could be measured; and the mi-
gratory behavior of adoptively transferred, fluorescently labeled
leukocytes at specific intranodal locations could be assessed by
two-photon microscopy. These experiments would need to be
carefully controlled given that lymph and lymph-borne DCs are
known to control lymphocyte trafficking by regulating the struc-
ture and function of high endothelial venules (54–57), and that
migratory DCs can cleave CCL21b to release a soluble form (15).
Moreover, lymph flow–induced wall shear stresses in the range of
those present in collecting lymphatics regulate LEC signaling by
modulating NO production (58, 59), histamine release (60), and
calcium dynamics (61), and further studies are required to deter-
mine if shear stress alters chemokine production and ACKR4
function in LECs. Wall shear stresses in the SCS are in the same
range as those in collecting lymphatics (28). However, these ef-
fects may depend on nodal LEC location because, in our model of
lymph flow in PLN (28), shear stress under basal afferent flow
ranges from .5 dyn/cm2 near the Af to ,1 dyn/cm2 closer to the
medulla.
The model predictions need to be considered in the context of its
limitations. We made some necessary simplifications that did not
take into account the inherent heterogeneity in LNs. We assumed,
for example, that chemokine production, cell population density,
and receptor availability was uniform across each LN region. The
effects of leukocyte recruitment, migration, and departure were
also not included; although the model could be coupled to models
of cell migration to investigate cellular chemotaxis and haptotaxis
in the LN (62, 63). Nonetheless, to our knowledge, the inclusion of
the number of physical and biological phenomena shown in Fig. 1
makes this the most thorough model characterization in the lit-
erature. Previous models captured only subsets of these phenom-
ena as parts of efforts to characterize simplified reductionist
experiments (4, 5, 28, 64, 65), or actions of single cells in sim-
plified environments (29, 31, 66, 67).
The reliability of the model outputs also clearly depends on the
accuracy of the input data. Many input parameters were collected
from experimental data, but these may not precisely reflect cir-
cumstances in vivo. Other parameters used have not been mea-
sured experimentally, or are currently impossible to measure, so
sensible estimates had to be included. The PVA helps determine
which parameters are likely to be the key regulators of the model
outputs and their accurate measurement, using primary sources of
tissue or cells, is a priority for future refinement of the model. As
discussed above, gradient location and directionality was robust
in the PVA, but, not unexpectedly, variation in ECM binding site
availability, effective diffusivity, and production of CCL19 or
CCL21 emerged as the key parameters that strongly correlated with
changes in gradient magnitude, total amount of chemokine in the
LN, and/or chemokine concentration in efferent lymph. Interestingly,
there was a strong negative correlation between the number of
ACKR4 receptors on the SCS ceiling and the concentration of
CCL19 and CCL21 in efferent lymph. This was not apparent when
we removed ACKR4 from the baseline simulation, presumably
because the input parameters we used in this simulation did not result
in enough chemokine entering the SCS or efferent lymph for an
effect of ACKR4 loss to be observed. Nonetheless, it emphasizes that
a role for intranodal ACKR4 under normal lymph flow conditions
cannot be excluded, at least in terms of regulating chemokine in
efferent lymph, and it will be of interest to see if CCL19 and CCL21
are elevated in the efferent lymph of unchallenged Ackr4-deficient
mice. If so, this could affect the behavior of lymph-borne leuko-
cytes and/or modify chemokine gradients in LNs further down the
LN chain in a manner akin to that discussed above for chemokine
entering LNs from nonlymphoid tissue.
In summary, by integrating our knowledge of lymph transport in
LNs with multiple biochemical processes describing the CCL19–
CCL21–CCR7–ACKR4 network, we have built a comprehensive
model of CCL19 and CCL21 transport and gradient formation in
the LN. The model reliably reproduces the available experimental
data, but more importantly has offered alternative interpretations
of experimental data and created new testable hypotheses. It has
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identified the key physical and biochemical parameters that are
likely to be critically important in controlling chemokine distri-
bution and gradient formation, and, by extension, leukocyte mi-
gration and immune responses. Incorporating additional, and more
accurate, experimental data will bring further power to the model.
These data will come from the many experiments discussed above,
but it will also be important to analyze primary LN cells to more
precisely quantify key model parameters, such as the number of
surface CCR7 molecules on LN leukocytes, the rate of CCL19/21
production by stromal cells, and the efficiency of ACKR4-
mediated scavenging by SCS ceiling LECs. Including other che-
mokines and their receptors, such as CXCL13/CXCR5 and
oysterols/EBI2, will also be of interest and will allow competing
intranodal gradients to be considered. Moreover, our computa-
tional model could be readily employed to investigate gradient
formation in other tissues and as a tool to identify key factors
regulating leukocyte migration in health and disease.
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